Logo image of TALS

TALARIS THERAPEUTICS INC (TALS) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:TALS - US87410C1045 - Common Stock

2.72 USD
-0.02 (-0.73%)
Last: 10/19/2023, 8:10:51 PM
2.75 USD
+0.03 (+1.1%)
After Hours: 10/19/2023, 8:10:51 PM
Buy % Consensus

43

ChartMill assigns a Buy % Consensus number of 43% to TALS. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 20.4. This target is 650% above the current price.
  • TALS was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about TALS.
  • In the previous month the buy percentage consensus was at a similar level.
  • TALS was analyzed by 6 analysts. More opinions would make the average more meaningful.

Related screens

TALS Historical Analyst RatingsTALS Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -27 -24 -21 -18 -15 -12 -9 -6 -3 0 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 2.7220.2020.4020.4021.00 - 642.65% 650.00% 650.00% 672.06%

Related screens

TALS Current Analyst RatingTALS Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5
Up and Down Grades
Date Firm Action Rating
2023-04-17 HC Wainwright & Co. Downgrade Buy -> Neutral
2023-02-23 Morgan Stanley Maintains Equal-Weight
2023-01-30 HC Wainwright & Co. Reiterate Buy
2022-10-24 HC Wainwright & Co. Maintains Buy
2022-10-20 SVB Leerink Maintains Market Perform
2022-10-20 HC Wainwright & Co. Initiate Buy
2022-09-09 Morgan Stanley Maintains Equal-Weight
2022-07-05 Morgan Stanley Downgrade Overweight -> Equal-Weight
2022-07-01 SVB Leerink Downgrade Outperform -> Market Perform
2022-05-24 Morgan Stanley Maintains Overweight
2022-05-13 SVB Leerink Maintains Outperform
2021-11-12 SVB Leerink Maintains Outperform
2021-06-01 Guggenheim Initiate Buy
2021-06-01 SVB Leerink Initiate Outperform
2021-06-01 Evercore ISI Group Initiate Outperform
2021-06-01 Morgan Stanley Initiate Overweight

TALARIS THERAPEUTICS INC / TALS FAQ

What do analysts expect the price target to be for TALARIS THERAPEUTICS INC (TALS)?

6 analysts have analysed TALS and the average price target is 20.4 USD. This implies a price increase of 650% is expected in the next year compared to the current price of 2.72.


What is the consensus rating for TALS stock?

The consensus rating for TALARIS THERAPEUTICS INC (TALS) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.